Roopom Banerjee
Executive Chairman Saga Diagnostics AB
Seminars
Thursday 25th September 2025
Ultra-sensitive PathlightTM MRD Detects Recurrence Sooner, Enabling Therapeutic Intervention Earlier
11:50 am
- PathlightTM MRD's novel approach tracking structural variants has enabled best in class performance in early Breast Cancer
- Commercial launch and positive MolDx coverage decision of PathlightTM in early breast cancer have expanded access for clinicians and patients
- SAGA is enabling pharma access to this test to drive earlier therapeutic intervention for novel therapeutics in early breast cancer
